Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9252W HIGH $1.92
Volume
71.86 K
Value Traded
270.16 K
Short % Float
1.83%
+0.81%Week
-5.7%1 Month
-8.82%3 Month
+19.23%6 Month
-92.23%5 Year
-99.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
111.85 M
EPS (TTM)
-0.29
P/E Ratio
-
Ent. Value
91.96 M
Total Shares
90.20 M
Float Shares
37.84 M
Insiders
58.05%
Institutions
5.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VANI Catalyst Timeline
Dated clinical, regulatory and corporate events for Vivani Medical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vivani Medical, Inc.
335Total events
8Upcoming
58Tier-1 (high impact)
2014 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteNPM-139Trial
Full enrollment and successful initial dosing of all participants in SLIM-1 trial
chronic weight managementsource ↗
▲Enrollment CompleteNPM-139Trial
Full enrollment and dosing of all 20 participants in SLIM-1
chronic weight managementsource ↗
▲First Patient DosedNPM-139Trial
First 10 participants dosed in SLIM-1 trial
chronic weight managementsource ↗
▲Partnership / LicenseNPM-139Corporate
Vivani ลงนามข้อตกลงกับ Novo Nordisk เพื่อประเมิน NPM-139
การจัดการภาวะน้ำหนักตัวเกินเรื้อรังsource ↗
▲Partnership / LicenseNPM-139Corporate
Non-exclusive agreement with Novo Nordisk to evaluate NPM-139
▲Runway Guidance UpdateCorporate
Additional $21.25M committed capital through July 2026 from equity purchase agreements
▲Partnership / LicenseNPM-139Corporate
Agreement with Novo Nordisk to evaluate NPM-139 and NanoPortal technology
▲Trial InitiationNPM-139Trial
HREC approval to initiate SLIM-1 trial
chronic weight managementsource ↗
◆Oral PresentationPresentation
CEO Adam Mendelsohn presents company overview at 2026 BIO International Convention
◆Oral PresentationPresentation
CEO Adam Mendelsohn presents at Jefferies Global Healthcare Conference
◆Trial InitiationNPM-139Trial
Phase 1 first-in-human study start planned for mid-2026
long-term weight regulationsource ↗
◆Trial CompletionNPM-139Trial
Phase 1 study of NPM-139 initiation in mid-2026
chronic weight managementsource ↗
◆Trial InitiationNPM-139Trial
คาดว่าจะเริ่มการศึกษาวิจัยทางคลินิกระยะที่ 1 แบบสุ่ม ในมนุษย์เป็นครั้งแรก เพื่อประเมิน NPM-139
การจัดการภาวะน้ำหนักตัวเกินเรื้อรังsource ↗
▲Preclinical PoCNPM-139Preclinical
Preclinical proof of concept for semaglutide implant: >20% sham-adjusted weight loss for one year
chronic weight managementsource ↗
▼Equity OfferingCorporate
Raised $41.5M in gross proceeds from multiple financings in 2025 and 2026 YTD
▼Equity OfferingCorporate
Pricing of common stock offering at $1.48 per share for gross proceeds of ~$4.5M
▲Oral PresentationOrionPresentation
6-year Early Feasibility Study results presented at NANS 2026
blindnesssource ↗
◆Poster PresentationOrionPresentation
Poster presentation of Orion Visual Cortical Prosthesis System at NANS 2026
blindnesssource ↗
▼Equity OfferingCorporate
Pricing of common stock offering at $1.62 per share for gross proceeds of ~$15.7M
▼Program DiscontinuationCorporate
Withdrawal of record date for Cortigent spin-off due to U.S. government shutdown
▲Trial CompletionNPM-115Trial
LIBERATE-1 Phase 1 clinical study completed
first-in-human test of NanoPortal implant technologysource ↗
◆Oral PresentationPresentation
CEO Adam Mendelsohn presents at H.C. Wainwright 27th Annual Global Investment Conference
●Quarterly UpdateCorporate
Reported Q2 2025 financial results; cash balance $8.1M as of June 30, 2025
▼Equity OfferingCorporate
Vivani entered into share purchase agreement for $10M private placement
▲Preclinical PoCNPM-139Preclinical
NPM-139 preclinical study showed ~20% weight loss maintained >6 months with single implant
obesitysource ↗
▲Topline ReadoutNPM-115Clinical Data
LIBERATE-1 Phase 1 study of NPM-115 met primary objectives with positive safety and tolerability
obesitysource ↗
▲Preclinical PoCNPM-139Preclinical
Preclinical data showed 20% weight loss sustained over >7 months
chronic weight managementsource ↗
▲Full ResultsNPM-115Clinical Data
LIBERATE-1 Phase 1 study results reported: positive safety, tolerability, and PK profile
obese or overweight subjectssource ↗
◆Oral PresentationPresentation
Vivani Medical to present at 2025 BIO International Convention
▲Preclinical PoCExenatidePreclinical
Exenatide implant shows durable body weight effects in rats
obesitysource ↗
▲FDA Filing AcceptedRegulatory Filing
Form 10 registration statement filed with SEC for Cortigent spin-off
▼Equity OfferingCorporate
Vivani entered into securities purchase agreement for $3M private placement
◆Oral PresentationPresentation
Vivani Medical to participate in virtual fireside chat hosted by H.C. Wainwright & Company
▲Partnership / LicenseOKV-119Corporate
Expanded collaboration with Okava Pharmaceuticals to include dogs for OKV-119
weight management, diabetes, cardiometabolic conditionssource ↗
Past FDA Catalysts and PDUFA Decisions
How VANI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | Exenatide NanoPortal implant | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$6M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 69%
Micro Cap(rank 454 of 658)
Percentile Rank
Vivani Medical, Inc. faces pipeline headwinds (30/100), with $138M risk-adjusted pipeline value, led by Exenatide in Overweight and Obesity (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exenatide Small moleculeCompletedNCT05670379 | Overweight and Obesity | Phase 1 | COMPLETED | 24 | Aug 21, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every VANI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NPM-139 | chronic overweight management | 2026-07-08 | significant efficacyRead More | Vivani Medical เข้าทำข้อตกลงกับ Novo Nordisk เพื่อประเมิน NPM-139 ซึ่งเป็นอุปกรณ์ส่งยาเซมากลูไทด์ชนิดฝังขนาดเล็กที่ออกฤทธิ์ยาวนานเป็นพิเศษสำหรับการจัดการภาวะน้ำหนักตัวเกินเรื้อรังRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Williams GreggDirector, 10% Owner | Buy | 793,650 36,912,736 held | $1.26 | 07/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VANI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VANI for Q2 2026. | ||||
VANI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VANI ranks across every disease it competes in
Competitive Position is a premium feature
See how VANI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVANI News
VANI▲ +7.2%on this news
Vivani Medical Announces Participation in Upcoming Investor Conferences
Vivani Medical, Inc. announced its participation in two upcoming investor conferences, including the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company aims to showcase its innovative NanoPortal technology, which is designed to enhance drug delivery for metabolic diseases. This participation highlights Vivani's commitment to advancing its clinical-stage biopharmaceutical developments.
Read more →VANIVivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical reported positive progress in its Phase 1 trial of NPM-139, a semaglutide implant for chronic weight management, with all participants successfully dosed. The company anticipates sharing top-line data in November 2026, which may lead to a Phase 2 trial in 2027. Additionally, Vivani has entered a partnership with Novo Nordisk and is completing a merger with ClearOne.
Read more →VANIVivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical has successfully dosed all participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature semaglutide implant. The trial aims to assess the safety and pharmacokinetics of the implant compared to Wegovy. Top-line results are anticipated in November 2026, with plans for a Phase 2 trial in 2027. The trial highlights Vivani's commitment to innovative weight management solutions.
Read more →VANIVivani Medical to Present at the Emerging Growth Conference on July 15, 2026
Vivani Medical, Inc. will present at the Emerging Growth Conference on July 15, 2026. CEO Adam Mendelsohn will provide a company update and answer questions from attendees. The presentation aims to highlight Vivani's innovative GLP-1 drug implants designed for improved patient adherence. An archived webcast will be available post-conference.
Read more →VANI▲ +18.5%on this news
Vivani Medical Menandatangani Perjanjian dengan Novo Nordisk bagi Menilai NPM-139, Implan Semaglutide Miniatur dengan Tindakan Ultra Jangka Panjang bagi Pengurusan Berat Badan Kronik
Vivani Medical has entered into a new agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant aimed at chronic weight management. The agreement reflects Novo Nordisk's interest in Vivani's technology. Vivani plans to begin a Phase 1 study in mid-2026 to assess the safety and tolerability of NPM-139, with the potential for further development based on initial results.
Read more →VANI▲ +18.5%on this news
Vivani Medical Mengadakan Perjanjian dengan Novo Nordisk untuk Mengevaluasi NPM-139, Implan Semaglutide Miniatur dengan Kerja Sangat Panjang untuk Pengelolaan Berat Badan Kronis
Vivani Medical has announced a new agreement with Novo Nordisk to evaluate NPM-139, a long-acting semaglutide implant for chronic weight management. This agreement highlights Novo Nordisk's interest in Vivani's technology. Vivani plans to initiate a Phase 1 clinical trial for NPM-139 in mid-2026, comparing it with Wegovy® to assess safety and tolerability.
Read more →VANI▲ +18.5%on this news
Vivani Medical schließt Vereinbarung mit Novo Nordisk zur Evaluierung von NPM-139, einem miniaturisierten, ultra-langwirkenden Semaglutid-Implantat zur langfristigen Gewichtsregulierung
Vivani Medical has announced a new agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant designed for long-term weight management. This collaboration underscores the interest in Vivani's innovative technology. A Phase I clinical trial is set to begin in mid-2026, aiming to assess the safety and pharmacokinetics of NPM-139.
Read more →VANIVivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical has signed an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant aimed at chronic weight management. The partnership reflects confidence in Vivani's technology and its potential market opportunity. A Phase 1 study is expected to begin in mid-2026 to assess the safety and tolerability of NPM-139 compared to Wegovy injections.
Read more →VANIVivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
Vivani has announced a merger agreement between its wholly owned subsidiary, Cortigent, Inc., and ClearOne, Inc., which is listed on Nasdaq. This strategic move is expected to enhance Vivani's market position and operational capabilities. The merger signifies a significant step in Vivani's growth strategy.
Read more →VANIClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
ClearOne has announced a merger agreement with Cortigent, Inc., a subsidiary of Vivani Medical. This strategic move aims to enhance ClearOne's market position and expand its product offerings. The merger is expected to leverage Cortigent's resources and expertise in the industry.
Read more →VANI▲ +5.3%on this news
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
Vivani Medical has appointed August J. Moretti to its board of directors, replacing Dr. Dean Baker, who is retiring. Moretti brings extensive experience in finance and operations, which will be crucial as Vivani advances its semaglutide implant, NPM-139. The company focuses on developing innovative drug delivery systems to enhance treatment adherence for chronic diseases.
Read more →VANI▼ -6.6%on this newsshared move
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Vivani Medical has received approval from Bellberry to initiate the SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant aimed at obesity management. The trial will assess the safety, tolerability, and pharmacokinetics of the implant in overweight subjects. The company is preparing for a subsequent trial, SLIM-2, contingent on positive results from SLIM-1.
Read more →VANI▲ +5.3%on this newsshared move
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present at the 2026 BIO International Convention in San Diego. The presentation will focus on the company's innovative drug implants designed to enhance medication adherence for patients with metabolic diseases. The event is scheduled for June 24, 2026, at 2:15 p.m. PT.
Read more →VANIVivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will include an overview of the company's innovative drug delivery systems and their potential to enhance patient adherence to medication. Following the presentation, a replay will be available on Vivani's website.
Read more →VANIVivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Vivani Medical has released its financial results for the first quarter of 2026. The report includes a business update, although specific details regarding financial performance or strategic initiatives were not provided in the article. The announcement is part of the company's ongoing communication with stakeholders.
Read more →VANI▼ -5.6%on this news
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vivani Medical reported its financial results for Q4 and full year 2025, highlighting the successful completion of its first-in-human study, LIBERATE-1, and promising preclinical data for its semaglutide implant, NPM-139. The company anticipates initiating a Phase 1 clinical study in mid-2026, supported by a solid cash position from recent financings. Despite a net loss of $26.6 million for the year, Vivani remains focused on advancing its GLP-1 implant candidates.
Read more →VANIVivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Vivani Medical's subsidiary, Cortigent, presented positive results from a 6-year Early Feasibility Study of the Orion Visual Cortical Prosthesis System at the NANS annual meeting. The device aims to provide visual perception to blind individuals through advanced neurostimulation technology. Cortigent's CEO expressed optimism about moving forward with a larger pivotal trial to seek FDA marketing approval.
Read more →VANI▲ +8%on this newsshared move
Vivani Medical, Inc. Announces Closing of Common Stock Offering
Vivani Medical, Inc. has announced the successful closing of a common stock offering, raising approximately $4.5 million. The offering consisted of 1,689,200 shares sold at $1.48 each, along with a private placement of 1,351,351 shares. The funds will support the company's ongoing research and clinical development efforts.
Read more →VANIVivani Medical, Inc. Announces Pricing of Common Stock Offering
Vivani Medical, Inc. has announced a best efforts registered direct offering of 1,689,200 shares of common stock priced at $1.48 per share. A concurrent private placement will involve 1,351,351 shares also at the same offering price, primarily purchased by the Company's Chairman. The total gross proceeds are anticipated to be around $4.5 million, earmarked for funding clinical research and general corporate purposes. The offerings are set to close around January 27, 2026, pending customary closing conditions.
Read more →About Vivani Medical, Inc.
Headquarters1350 S. LOOP ROAD, ALAMEDA, CA, 94502
BIOPHARMAWATCH ELITE PLUS
Trade the next VANI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime